Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Alcohol drinking pattern impacts coronary heart disease

A fascinating study published in the BMJ shows that although the French drink more than the Northern Irish each week, as they drink daily, rather than more on less occasions, the French suffered from considerably less coronary heart disease than the Northern Irish.

3 Dec 2010

SAGE launches two new journals in Drug Safety, Hematology

SAGE Expands Therapeutic Advances series by launching two new journals in Drug Safety and Hematology. SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Drug Safety, and Therapeutic Advances in Hematology.

3 Dec 2010

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that preliminary results from its cancer stem cell program, targeting the CD47 protein, will be reported in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida, December 4-7, 2010.

2 Dec 2010

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen today announced that it will present data from several key Nplate (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.

2 Dec 2010

ASH honors Sen. Sherrod Brown and Erik Fatemi

The American Society of Hematology (ASH) will honor Senator Sherrod Brown (D-OH) with the 2010 ASH Award for Public Service and Erik Fatemi, Majority Clerk for the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS), with the Award for Outstanding Service in recognition of their dedication to championing health care and research issues. These awards will be officially announced at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando, FL.

2 Dec 2010

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline Therapeutics, Inc. today announced that two abstracts featuring SL-401 clinical efficacy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and pre-clinical activity in chronic myeloid leukemia (CML) have been selected for presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH) to be held in Orlando, FL from December 4-7, 2010.

2 Dec 2010

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it is initiating a multicenter Phase 2b clinical trial with its oncology drug candidate tamibarotene in combination with chemotherapeutical agents for the treatment of patients with advanced non-small-cell lung cancer (NSCLC).

2 Dec 2010

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7.

1 Dec 2010

ASH to host annual meeting for blood disorders at Orange Convention Center

The American Society of Hematology (ASH) will host its 52nd annual meeting at the Orange County Convention Center in Orlando, FL, December 4-7. More than 20,000 attendees are expected for this event, which will highlight emerging research trends in the diagnosis, treatment, and understanding of blood disorders.

1 Dec 2010

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that initial safety and efficacy data from its ongoing Phase II Study with resminostat, a pan-Histone Deacetylase (HDAC) Inhibitor, in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, USA.

1 Dec 2010

HOANNJ announces collaboration to enhance cancer care through United Network of US Oncology

Hematology Oncology Associates of Northern New Jersey, P.A. (HOANNJ), an independent physician-owned, single-specialty oncology practice with offices in Morristown and Parsippany, and US Oncology, Inc., the nation's leading integrated oncology company, today announced their new collaboration to protect, expand and enhance patient access to high-quality, evidence-based cancer care and clinical research through the United Network of US Oncology.

1 Dec 2010

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Cell Therapeutics, Inc. announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present end of study results for the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma at the 52nd Annual Meeting of the American Society of Hematology on Sunday, December 5, 2010 in Orlando, Florida.

1 Dec 2010

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD Pharmaceuticals, Inc. today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology being held in Orlando, Florida, December 4-7, 2010.

30 Nov 2010

IRIS announces product acquisition from BioMicro Systems

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that it has acquired the assets of a multi-purpose, bench-top instrument platform for automating highly repetitive, manual laboratory protocols for (F)ISH (fluorescence in-situ hybridization) testing and other slide-based cytogenetic applications.

30 Nov 2010

Array BioPharma to present data on ARRY-520 Phase 1 trial for multiple myeloma at ASH Annual Meeting

Array BioPharma Inc. today announced that it will present data from a Phase 1 trial of KSP inhibitor ARRY-520 in patients with relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on Saturday, December 4, 2010.

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

30 Nov 2010

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

Transgenomic, Inc. announced today the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc. This acquisition includes a suite of proprietary genetic commercial tests, certain proprietary biomarker assays, and the CLIA-certified laboratory operations of Clinical Data for a purchase price of approximately $15.4 million, primarily in cash and notes.

29 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients

Researchers with UCLA's Jonsson Comprehensive Cancer Center have found that melanoma patients whose cancers are caused by mutation of the BRAF gene become resistant to a promising targeted treatment through another genetic mutation or the overexpression of a cell surface protein, both driving survival of the cancer and accounting for relapse.

25 Nov 2010

Hematology News and Research

Further Reading

Alcohol drinking pattern impacts coronary heart disease

SAGE launches two new journals in Drug Safety, Hematology

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

ASH honors Sen. Sherrod Brown and Erik Fatemi

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

Pfizer to present data on hematology portfolio at ASH Annual Meeting

ASH to host annual meeting for blood disorders at Orange Convention Center

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

HOANNJ announces collaboration to enhance cancer care through United Network of US Oncology

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

IRIS announces product acquisition from BioMicro Systems

Array BioPharma to present data on ARRY-520 Phase 1 trial for multiple myeloma at ASH Annual Meeting

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News